The biotech company Relay has developed an experimental drug for people with vascular malformations. This medication targets people with a PIK3CA mutation (PIK3CA-driven malformation). The company now plans to test it in clinical trials worldwide.
The biotech company Relay has developed an experimental drug for people with vascular malformations. This medication targets people with a PIK3CA mutation (PIK3CA-driven malformation). The company now plans to test it in clinical trials worldwide.